chronic kidney disease-mineral and bone disorder
Conditions
Interventions
test group:Denosumab 60mg subcutaneously
Sponsors
Tianjin Hospital
Eligibility
Sex/Gender
Male
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The diagnosis of CKD-MBD with low bone mineral density is clear; 2. Males, aged 60 years and over; 3. Calcium, phosphorus, PTH metabolism is stable or the following standards are met after treatment: Calcium 2.2 - 2.6mmol/L, Phosphorus 0.87 - 1.45mmol/L, PTH 150 - 300pg/ml; 4. Complete clinical data; 5. Patient informed consent.
Exclusion criteria
Exclusion criteria: 1. Long-term bed rest; 2. Confirmed Cushing's syndrome, hypogonadism, hyperthyroidism, primary hyperparathyroidism, plasma cell disease, leukemia and lymphoma, myelodysplastic syndrome, systemic lupus erythematosus, rheumatoid arthritis, Osteogenesis imperfecta, primary and metastatic bone tumors and other primary diseases that may lead to secondary osteoporosis; 3. Long-term use of glucocorticoids, anticonvulsants, methotrexate, cyclosporine, thyroid hormones, aluminum-containing antacids, etc.; 4. In the past 3 months, the use of estrogen, calcitonin, bisphosphonates, teriparatide, Xianling Gubao and other drugs affecting bone metabolism; 5. It is contraindicated in drug application such as history of allergy to denosumab and hypocalcemia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ca;P;BAP;PINP;ß-CTX;bone mineral density; | — |
Countries
China
Contacts
Public ContactYang Dingwei
Tianjin Hospital
Outcome results
None listed